RT Journal Article
SR Electronic
T1 HIV-1 Vaccines and Adaptive Trial Designs
JF Science Translational Medicine
FD American Association for the Advancement of Science
SP 79ps13
OP 79ps13
DO 10.1126/scitranslmed.3001863
VO 3
IS 79
A1 Corey, Lawrence
A1 Nabel, Gary J.
A1 Dieffenbach, Carl
A1 Gilbert, Peter
A1 Haynes, Barton F.
A1 Johnston, Margaret
A1 Kublin, James
A1 Lane, H. Clifford
A1 Pantaleo, Giuseppe
A1 Picker, Louis J.
A1 Fauci, Anthony S.
YR 2011
UL http://stm.sciencemag.org/content/3/79/79ps13.abstract
AB Developing a vaccine against the human immunodeficiency virus (HIV) poses an exceptional challenge. There are no documented cases of immune-mediated clearance of HIV from an infected individual, and no known correlates of immune protection. Although nonhuman primate models of lentivirus infection have provided valuable data about HIV pathogenesis, such models do not predict HIV vaccine efficacy in humans. The combined lack of a predictive animal model and undefined biomarkers of immune protection against HIV necessitate that vaccines to this pathogen be tested directly in clinical trials. Adaptive clinical trial designs can accelerate vaccine development by rapidly screening out poor vaccines while extending the evaluation of efficacious ones, improving the characterization of promising vaccine candidates and the identification of correlates of immune protection.